According to global cancer statistics for 2020, ovarian cancer was projected to have 313959 new cases and 207252 deaths, rendering it the deadliest cancer of the female reproductive system.[10] Due to the lack of specific biomarkers and subtle early‐stage symptoms, most patients are diagnosed at advanced stages with poor prognosis, resulting in a five‐year survival rate below 30%.[11] Besides BRCA1/2, there are few effective therapeutic targets, underscoring the urgent need for novel biomarkers and treatment targets in ovarian cancer.[12, 13, 14]. The gene discussed is BRCA1; the disease is ovarian carcinoma.